Published data on the association between CYP3A4*1B polymorphism and cancer risk are inconclusive. To derive a more precise estimation of the association, we conducted a meta-analysis. A systematic search of the PubMed database was performed. A total of 55 separate studies including 22072 cancer cases and 25433 controls were involved in this meta-analysis. We found a significant association between CYP3A4*1B and cancer risk in the overall population in dominant model (AG+GG vs. AA: OR=1.142, 95% CI=1.006-1.295). No significant association was found in recessive model (GG vs. AG+AA: OR=1.156, 95% CI=0.941-1.419), heterozygous model (AG vs. AA: OR=1.109, 95% CI=0.977-1.259), or homozygous model (GG vs. AA: OR=1.213, 95% CI=0.950-1.549). We performed subgroup meta-analysis based on the difference of ethnicity and cancer type. Ethnic subgroup analyses revealed no significant associations of African or Caucasian ethnicities in any genetic models. In the subgroup analysis by Cancer types, we observed an increased risk for leukemia in dominant model and heterozygous model. Excluding studies with controls not in HWE, a significant association was found in dominant model and heterozygous model. In summary, this meta-analysis suggests that the CYP3A4*1B polymorphism might play a modest role in susceptibility to cancer, especially for leukemia.
Keywords: CYP3A4 polymorphism; Cancer; Meta-analysis; Susceptibility.
© 2018 by the Association of Clinical Scientists, Inc.